PRESS RELEASE DEBIOPHARM UNDERLINES COMMITMENT TO ERADICATING ANTIMICROBIAL RESISTANCE BY SPONSORING THE 8TH ANNUAL WORLD AMR CONFERENCE • Antimicrobial resistance (AMR) is one of the top global public health threats. It is estimated that bacterial AMR was directly responsible for 1.27 million deaths in 2019 and indirectly contributed to 4.95 million deaths globally (1). [...] • Although antibiotics are essential drugs, being the foundation for global health and of modern medicine, the current investment in the development of new therapies is not sufficient to counteract the rise of AMR. [...] • Debiopharm is once again a major sponsor for the World Antimicrobial Resistance (World AMR) conference and will be driving the dialogue on Market Access with a presentation and roundtable discussion focusing on solutions to tackle reimbursement challenges. Lausanne, Switzerland – August 27th, 2024 – Debiopharm (www.debiopharm.com), a Swiss- based, global biopharmaceutical company, aiming [...] For the last decade, Debiopharm has been committed to developing new antimicrobials for patients by conducting research on a novel class of antibiotics that target hard-to-treat infections, caused by WHO priority pathogens. Now in its third year of sponsoring World AMR, Debiopharm is proud to support the conference’s mission to unite key decision-makers in AMR from international government bo [...] This year, Debiopharm’s Head of Global Value & Access, Jennifer Quinn, will present within the Impact, Policy and Awareness Track and lead a roundtable discussion on how to move the needle on fair reimbursement for antibiotics. Focused on actionable ways to leverage current reimbursement models, Jennifer’s presentation will outline a tangible framework for payer negotiations and discuss eviden [...] “We’re looking forward to open discussions and networking opportunities with public organizations and other infectious disease industry experts to put into place practical solutions to combat the reimbursement challenged that help to fuel AMR.” – Jennifer Quinn, Head of Global Value & Access. World AMR 2023 Session details Congress agenda Speaker Presentation Sept. [...] 5th 11:20AM EST How can current reimbursement models be leveraged while waiting for 'pull incentives'? Jennifer Quinn, Head of Global Value & Access Roundtable discussion What data is needed to fit current payer evidence Jennifer Quinn,Sept. [...] Head of Global Value & Access About afabicin Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor, selectively targeting Staphylococcus’ essential bacterial fatty acid biosynthesis pathway. [...] Afabicin is active against Staphylococcus spp., of which methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. [...] As a result of high selectivity, FabI inhibitors specifically target selected pathogens, and potentially preserve intestinal microbiota.
- Pages
- 2
- Published in
- Canada
